drugset
drugset / Trial / NCT01227291

SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg

NCT01227291 ↗

Phase 1/2 Completed 30 enrolled Sylentis, S.A.
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the tolerance and effect on unmedicated subjects with elevated IOP.

Timeline

Start
2010-10
Primary completion
2012-03
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject bamosiran Unknown — Other

Indications

glaucoma ocular hypertension